Pharmacokinetics and Safety of MB-102 (Relmapirazin) and the MediBeacon Transdermal GFR Measurement System in Evaluation of Kidney Function in Normal and Renal Compromised Subjects
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 249 participants.
Also called NCT05425719
- Study
- In this atlas
Overview
- Design
- Interventional study; non-randomized; no masking; primary purpose other
- Phase
- Phase 3
- Enrolled
- 249 participants
- Sponsor
- MediBeacon
- Registry
-
NCT05425719
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, China
- Registry status
- Completed
Technical summary
Registry record NCT05425719. Non-randomized; no masking; primary purpose other. Start 2022-06-14 (actual); primary completion 2023-02-15 (actual). Results posted on 2024-04-18.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Pharmacokinetics and Safety of MB-102 (Relmapirazin) and the MediBeacon Transdermal GFR Measurement System in Evaluation of Kidney Function in Normal and Renal Compromised Subjects
- Condition
- Chronic Kidney Disease
- Intervention (Drug)
- MB-102
- Intervention (Device)
- MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)
- Lead sponsor
- MediBeacon
Record details
- Record id
cardio:ct-nct05425719- Content hash
c26af8ec7fb2469c8281b5e9b6e3a7d097db33001462a350ce0bc1a9c30eea03